A novel interaction between HER2/neu and cyclin e in breast cancer

Oncogene

Volumn 29, Issue 27, 2010, Pages 3896-3907

  Mittendorf, E A ^a   Liu, Y ^a,a   Tucker, S L ^a   McKenzie, T ^a   Qiao, N ^a   Akli, S ^a   Biernacka, A ^a   Meijer, L ^b   Keyomarsi, K ^a   Hunt, K K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b STATION BIOLOGIQUE   (France)

Author keywords

breast cancer; cell cycle regulation; cyclin E; HER2 neu

Indexed keywords

CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NITROBLUE TETRAZOLIUM; ROSCOVITINE; SMALL INTERFERING RNA; TRASTUZUMAB; TUMOR MARKER;

ADENOVIRUS; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER SURVIVAL; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL SELECTION; CELL STRAIN MCF 7; CELL VIABILITY; CLONOGENIC ASSAY; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; ENZYME ACTIVITY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MOLECULAR INTERACTION; MOLECULAR WEIGHT; MOUSE; NONHUMAN; ONCOGENE NEU; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA EXTRACTION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN E; DOWN-REGULATION; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; MOLECULAR WEIGHT; PROTEIN BINDING; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; SURVIVAL RATE; TRANSCRIPTION, GENETIC;

EID: 77954540202     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.151     Document Type: Article

References (36)

1. Akli S, Keyomarsi K. (2003). Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy. Cancer Biol Ther 2: S38-S47.
2. Akli S, Van Pelt CS, Bui T, Multani AS, Chang S, Johnson D et al. (2007). Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. Cancer Res 67: 7212-7222.
3. Akli S, Zheng PJ, Multani AS, Wingate HF, Pathak S, Zhang N et al. (2004). Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res 64: 3198-3208.
4. Bacus SS, Stancovski I, Huberman E, Chin D, Hurwitz E, Mills GB et al. (1992). Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells. Cancer Res 52: 2580-2589.
5. Brockhoff G, Heckel B, Schmidt-Bruecken E, Plander M, Hofstaedter F, Vollmann A et al. (2007). Differential impact of cetuximab, pertuzumab and trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation. Cell Prolif 40: 488-507.
6. Buckley MF, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, Nicholson RI et al. (1993). Expression and amplification of cyclin genes in human breast cancer. Oncogene 8: 2127-2133.
7. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L et al. (1999). Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2648.
8. Dulic V, Drullinger LF, Lees E, Reed SI, Stein GH. (1993). Altered regulation of G1 cyclins in senescent human diploid fibroblasts: accumulation of inactive cyclin E-Cdk2 and cyclin D1-Cdk2 complexes. Proc Natl Acad Sci USA 90: 11034-11038.
9. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R et al. (1992). Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) breast cancer study group. J Clin Oncol 10: 1049-1056.
10. Harwell RM, Porter DC, Danes C, Keyomarsi K. (2000). Processing of cyclin E differs between normal and tumor breast cells. Cancer Res 60: 481-489.
11. Keyomarsi K, Herliczek TW. (1997). The role of cyclin E in cell proliferation, development and cancer. Prog Cell Cycle Res 3: 171-191.
12. Keyomarsi K, O0Leary N, Molnar G, Lees E, Fingert HJ, Pardee AB. (1994). Cyclin E, a potential prognostic marker for breast cancer. Cancer Res 54: 380-385.
13. Keyomarsi K, Pardee AB. (1993). Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci USA 90: 1112-1116.
14. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN et al. (2002). Cyclin E and survival in patients with breast cancer. N Engl J Med 347: 1566-1575.
15. Lambert LA, Qiao N, Hunt KK, Lambert DH, Mills GB, Meijer L et al. (2008). Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. Cancer Res 68: 7966-7974.
16. Le XF, Bedrosian I, Mao W, Murray M, Lu Z, Keyomarsi K et al. (2006). Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway. Cell Cycle 5: 1654-1661.
17. Lee RJ, Albanese C, Fu M, D'Amico M, Lin B, Watanabe G et al. (2000). Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol Cell Biol 20: 672-683.
18. McCann AH, Dervan PA, O0Regan M, Codd MB, Gullick WJ, Tobin BM et al. (1991). Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res 51: 3296-3303.
19. Ohtsubo M, Roberts JM. (1993). Cyclin-dependent regulation of G1 in mammalian fibroblasts. Science 259: 1908-1912.
20. Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, Pagano M. (1995). Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 15: 2612-2624.
21. Porter DC, Zhang N, Danes C, McGahren MJ, Harwell RM, Faruki S et al. (2001). Tumor specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms. Mol Cell Biol 21: 6254-6269.
22. Potemski P, Kusinska R, Watala C, Pluciennik E, Bednarek AK, Kordek R. (2006). Cyclin E expression in breast cancer correlates with negative steroid receptor status, HER2 expression, tumor grade and proliferation. J Exp Clin Cancer Res 25: 59-64.
23. Rao S, Lowe M, Herliczek TW, Keyomarsi K. (1998). Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene 17: 2393-2402.
24. Roh H, Pippin J, Drebin JA. (2000). Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu. Cancer Res 60: 560-565.
25. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182.
26. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712.
27. Spruck CH, Won KA, Reed SI. (1999). Deregulated cyclin E induces chromosome instability. Nature 401: 297-300.
28. Timms JF, White SL, O'Hare MJ, Waterfield MD. (2002). Effects of ErbB-2 overexpression on mitogenic signalling and cell cycle progression in human breast luminal epithelial cells. Oncogene 21: 6573-6586.
29. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L et al. (2002). Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726.
30. Wingate H, Zhang N, McGarhen MJ, Bedrosian I, Harper JW, Keyomarsi K. (2005). The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27. J Biol Chem 280: 15148-15157.
31. Wright C, Angus B, Nicholson S, Sainsbury JR, Cairns J, Gullick WJ et al. (1989). Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 49: 2087-2090.
32. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. (2002). Herceptin-induced inhibition of phosphatidy-linositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 62: 4132-4141.
33. Yang HY, Zhou BP, Hung MC, Lee MH. (2000). Oncogenic signals of HER-2/neu in regulating the stability of the cyclin-dependent kinase inhibitor p27. J Biol Chem 275: 24735-24739.
34. Yarden Y, Sliwkowski MX. (2001). Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137.
35. Yu D, Hung MC. (2000). Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 19: 6115-6121.
36. Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC. (2001). Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phos-phorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 3: 245-252.